Hormone receptor-positive (HR +) breast cancer is the most common subtype, and while endocrine therapy remains the backbone of HR + MBC treatment, an increasing number of targeted therapies are becoming options for patients with specific genomic variants (e.g., PIK3CAmut, ESR1mut, AKTmut, PTENmut) [2–4]. Here, NR4A1 is linked to breast carcinoma.